Method for quantifying drug concentration in prodrug compositions

Through the combination of dual enzymatic digestion and liquid chromatography/high resolution mass spectrometry, the problem of difficult to quantify the drug load in cross-linked hyaluronic acid hydrogels is solved, and the accurate measurement and release control of the drug load is achieved. Improves the stability and half-life of the drug in the body.

CN113795590BActive Publication Date: 2024-11-26GENZYME CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202080034089.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-07
Filing Date
2020-05-06
Publication Date
2024-11-26
Estimated Expiration
2040-05-06

AI Technical Summary

Technical Problem

The prior art is difficult to accurately quantify the amount of drug loaded in crosslinked hyaluronic acid hydrogels and control the drug release rate, especially in the aqueous environment of hydrogels, traditional methods such as UV measurement are not applicable and use elevated temperatures. Or pH causes partial degradation of the drug, resulting in heterogeneous mixtures that are difficult to quantify.

Method used

Dual enzymatic digestion method is adopted, firstly using hyaluronidase to digest crosslinked hyaluronic acid, followed by proteolytic enzyme digestion, producing homogeneous peptide digestion products, and by liquid chromatography/high resolution mass spectrometry (LC/HRMS) is tested and quantified to ensure the accuracy and selectivity of drug load.

Benefits of technology

Accurate quantification of drug load in crosslinked hyaluronic acid hydrogels, improves the half-life of the drug in the body, increases from minutes to days, and the method is faster and more efficient than traditional NMR methods, and contaminates The interference is lower.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113795590B_ABST
    Figure CN113795590B_ABST
Patent Text Reader

Abstract

Methods for quantifying the amount of drug present in a prodrug composition are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 844,579, filed on May 7, 2019, the entire disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention relates to methods for quantifying the amount of drug present in a prodrug composition. Background Art

[0004] Over the past decade, an average of 17 new peptides have entered clinical trials each year, the approval rate (from phase 1 to market) is twice that of small molecules (Dharanipragada (2013) Future Medicinal Chemistry 5(7):831; (2013) Drug Discovery Today 18:807-817), and there are more than 150 candidate peptide drugs currently in development (Lau and Dunn (2018) Bioorganic & Medicinal Chemistry 26:2700-2707).

[0005] However, the development of peptide drugs presents specific challenges. For example, peptide drugs are proteolytically cleaved and rapidly cleared in vivo. Oral delivery remains challenging, in part due to the low permeability of biological membranes. Attempts have been made to remedy these shortcomings by incorporating conformational restrictions such as cyclic peptide formation (e.g., by lactamization and click cyclization), hydrocarbon stapling, and lipidation and developing polymer drug conjugates.

[0006] An example of a peptide drug is SAR425899, a dual receptor agonist that targets glucagon and GLP1 receptors and can promote glycemic control and weight loss in patients with type 2 diabetes, as well as weight loss in healthy volunteers (Tillner et al. (2019) Diabetes Obes. Metab. 21:120, doi:10.1111 / dom.13494, Epub 2018 Sep 16). However, due to rapid clearance in the body, a once-daily dose of SAR425899 is required.

[0007] Hyaluronic acid (HA), also known as hyaluronan, is a naturally occurring non-sulfated linear polysaccharide composed of repeating disaccharide units of d-glucuronic acid and N-acetyl-d-glucosamine linked by β-1-3 and β-1-4 glycosidic bonds (Khunmanee et al. (2017) J. Tissue Engineering Vol. 8 (doi:doi.org / 10.1177 / 2041731417726464)). HA is an important structural element in the skin and participates in many cell surface receptor interactions. HA has immunosuppressive and anti-angiogenic activities and is present in brain tissue, hyaline cartilage and synovial joint fluid. Due to its strong hydrophilic characteristics and its high molecular weight in biological tissues (it can absorb large amounts of water, up to 1000 times its solid volume), HA plays an important structural and functional role in the body.

[0008] Due to its biocompatibility and biodegradability, many applications of HA have been found in biomedical and pharmaceutical applications. However, HA is highly soluble and often exhibits very poor mechanical properties and rapid degradation behavior in vivo. Therefore, HA has been chemically modified and / or cross-linked to improve its properties, including mechanical properties, viscosity, solubility, degradation and biological properties. HA derivatives have been produced and used in tissue engineering scaffolds, soft tissue surgery (such as vocal cord enhancement), drug delivery, intracellular delivery of siRNA, wound healing, and as instruments for surgical procedures.

[0009] Cross-linked hyaluronic acid (xHA) forms hydrogels of millions of daltons in aqueous environments and can be linked to drugs (e.g., peptide drugs) to stabilize the drugs in vivo. However, it is difficult to quantify the amount of drug loaded in the hydrogel and the rate at which the drug is released from the hydrogel. Simple UV measurements, which are typically used for basic quantification of peptides in solution, cannot be used for hydrogels because such analysis requires that the drug-linked hydrogel complex is completely dissolved.

[0010] Alternative methods using elevated temperature or elevated pH to accelerate the hydrolysis of the linker and release of the peptide drug result in partial degradation of the peptide drug, thus producing a heterogeneous mixture that is difficult to quantify. Therefore, an analytical quantitative method is needed to quantify the drug loading of the prodrug composition on the cross-linked HA hydrogel. Summary of the invention

[0011] In order to solve the analytical challenges in determining the drug loading on cross-linked HA (xHA) hydrogels, for example, to enable the determination of the peptide loading of xHA hydrogels, a novel method was found that allows the drug loading (e.g., biopolymer peptide prodrug loading) measured as a weight / weight percentage to be accurately quantified. The method described herein is highly selective for drug loading determination, and the method can be applied to any small molecule (e.g., polypeptide, polynucleotide, etc.) that can be decomposed into smaller components (e.g., by proteolytic digestion, hydrolysis, etc.), and can be widely used in the determination of drug loading of prodrugs (e.g., prodrugs containing biopolymers). The method described herein can be used, for example, to control the dosage delivery of drugs in vivo, and to perform quality control of drug loading between prodrug batches during the manufacturing process. The method described herein enables the production of drugs (e.g., peptide drugs) that increase the half-life in vivo, such as drugs such as peptide drugs whose half-life increases from minutes to days.

[0012] The method described herein provides multiple advantages relative to previous methods known in the art (such as methods based on NMR). For example, compared with the method described herein, the method based on NMR takes longer time and has lower yield. The method based on NMR requires milligrams of material, while the novel method described herein only requires nanograms of material. In addition, the dynamic range of the method based on NMR is lower than the dynamic range of the novel method described herein. In addition, compared with the novel method described herein, the method based on NMR is more susceptible to interference from contaminated peptides.

[0013] This paper provides novel methods based on the following discovery: dual enzymatic digestion followed by quantification of one or more digestion products can be used to accurately quantify the drug loading (e.g., peptide drug loading) on ​​the hydrogel. In certain embodiments of the method, cross-linked hyaluronic acid-linker-peptide (xHA-LP) is incubated with enzyme to digest the cross-linked hyaluronic acid. Subsequently, proteolytic enzymes are used to digest the attached peptides and produce proteolytic digestion products. The proteolytic digestion products representing peptides are subsequently quantified.

[0014] In certain exemplary embodiments of the method, a cross-linked hyaluronic acid-linker-peptide conjugate (xHA-LP) is weighed and suspended in a buffer as a hydrogel. The hydrogel is enzymatically degraded into soluble oligomeric hyaluronic acid-linker-peptide (oHA-LP). The resulting oHA-LP oligomer exists in the form of a heterogeneous mixture, consisting of peptides, linkers, and oligomeric hyaluronic acids of varying lengths. This oligomeric hyaluronic acid heterogeneity is undesirable for quantification based on mass spectrometry, but can be applied to assays based on UV or fluorescence with lower specificity. Therefore, for a reference assay based on mass spectrometry, a second enzymatic (e.g., endoproteolysis) digestion step is introduced to digest the peptide drug and produce a homogeneous peptide digestion product (e.g., a 19-amino acid C-terminal peptide digestion product DFIEWLKAGGPSSGAPPPS-NH2( Figure 3 )). The peptide product can then be detected and quantified using an assay such as, for example, liquid chromatography / high resolution mass spectrometry (LC / MS).

[0015] In one aspect, a method for determining the amount of a drug present in a cross-linked hyaluronic acid-linker-peptide (xHA-LP) prodrug formulation is provided. The method comprises the steps of contacting a sample of the xHA-LP prodrug formulation with a hyaluronoglucosidase (e.g., hyaluronidase (HAase) or hyaluronic acid (HA) lyase) to produce an oligomeric hyaluronic acid-linker-peptide drug (oHA-LP); contacting the oHA-LP with an enzyme to produce a peptide digestion product of the drug; and detecting the peptide digestion product to determine the amount of the drug present in the xHA-LP prodrug formulation.

[0016] In certain exemplary embodiments, the peptide digestion product is between about 2 amino acids and about 100 amino acids in length, between about 3 amino acids and about 75 amino acids in length, between about 4 amino acids and about 50 amino acids in length, between about 6 amino acids and about 30 amino acids in length, between about 15 amino acids and about 20 amino acids in length, or about 19 amino acids in length. In certain exemplary embodiments, the peptide digestion product is about 1, about 2, or about 3 amino acids in length.

[0017] In certain exemplary embodiments, the step of detecting the peptide digestion products is performed by a method selected from one or a combination of liquid chromatography-mass spectrometry (LC-MS), liquid chromatography tandem mass spectrometry (LC-MS-MS), liquid chromatography-high resolution mass spectrometry (LC-HRMS), ultraviolet (UV) absorption and fluorescence detection.

[0018] In certain exemplary embodiments, the hyaluronoglucosidase is a HAase selected from HAase 1, HAase 2, HAase 3, HAase 4, HAase 5, and HAase 6. In other exemplary embodiments, the hyaluronoglucosidase is HAase 1 or HAase 2. In yet other exemplary embodiments, the hyaluronoglucosidase is HAase 2. In certain exemplary embodiments, the hyaluronoglucosidase is HA lyase EC 4.2.2.1.

[0019] In certain exemplary embodiments, the oHA-LP is contacted with an intracellular protease (e.g., Glu-C, Asp-N, Lys-C, Arg-C, trypsin, and chymotrypsin). In certain exemplary embodiments, the intracellular protease is Asp-N.

[0020] In certain exemplary embodiments, the method further comprises using an internal standard. In certain exemplary embodiments, the internal standard comprises one or more heavy isotopes.

[0021] In certain exemplary embodiments, a calibration curve is used to determine the amount of drug present.

[0022] In certain exemplary embodiments, the xHA-LP is contacted with the hyaluronoglucosidase in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 5 KPSI, about 10 KPSI, or about 15 KPSI.

[0023] In certain exemplary embodiments, the oHA-LP is contacted with the second enzyme in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 35 KPSI, about 40 KPSI, or about 45 KPSI.

[0024] In another aspect, a method for determining the amount of a drug present in a cross-linked hyaluronic acid-linker-peptide (xHA-LP) prodrug formulation is provided. The method comprises the steps of: contacting a sample of the xHA-LP prodrug formulation with a hyaluronoglucosidase to produce an oligomeric hyaluronic acid-linker-peptide drug (oHA-LP); contacting the oHA-LP with an intracellular protease to produce a peptide digestion product of the drug; and detecting the peptide digestion product to determine the amount of the drug present in the xHA-LP prodrug formulation.

[0025] In certain exemplary embodiments, the step of detecting the peptide digestion products is performed by a method selected from one or a combination of LC-MS, LC-MS-MS, LC-HRMS, UV absorption and fluorescence detection.

[0026] In certain exemplary embodiments, the hyaluronoglucosidase is HAase 1 or HAase 2. In certain exemplary embodiments, the hyaluronoglucosidase is HA lyase EC 4.2.2.1.

[0027] In certain exemplary embodiments, the intracellular protease is selected from the group consisting of Glu-C, Asp-N, Lys-C, Arg-C, trypsin, and chymotrypsin.

[0028] In certain exemplary embodiments, the intracellular protease is Asp-N.

[0029] In certain exemplary embodiments, the method further comprises using an internal standard. In certain exemplary embodiments, wherein the internal standard comprises one or more heavy isotopes.

[0030] In certain exemplary embodiments, a calibration curve is used to determine the amount of drug present.

[0031] In certain exemplary embodiments, the xHA-LP is contacted with the hyaluronoglucosidase in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 5 KPSI, about 10 KPSI, or about 15 KPSI.

[0032] In certain exemplary embodiments, the oHA-LP is contacted with the intracellular protease in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 35 KPSI, about 40 KPSI, or about 45 KPSI.

[0033] In another aspect, a method for determining the amount of a drug present in a cross-linked hyaluronic acid-linker-peptide (xHA-LP) prodrug formulation is provided. The method comprises the steps of: contacting the xHA-LP prodrug with hyaluronidase 2 to produce an oligomeric hyaluronic acid-linker-peptide drug (oHA-LP); contacting the oHA-LP with Asp-N to produce a peptide digestion product of the drug; and detecting the peptide digestion product to determine the amount of the drug present in the xHA-LP prodrug formulation.

[0034] In certain exemplary embodiments, the peptide digestion product is between about 2 amino acids and about 100 amino acids in length, between about 3 amino acids and about 75 amino acids in length, between about 4 amino acids and about 50 amino acids in length, between about 6 amino acids and about 30 amino acids in length, between about 15 amino acids and about 20 amino acids in length, or about 19 amino acids in length. In certain exemplary embodiments, the peptide digestion product is about 1, about 2, or about 3 amino acids in length.

[0035] In certain exemplary embodiments, the step of detecting the peptide digestion products is performed by a method selected from one or a combination of LC-MS, LC-MS-MS, LC-HRMS, UV absorption and fluorescence detection.

[0036] In certain exemplary embodiments, the method further comprises using an internal standard. In certain exemplary embodiments, the internal standard comprises one or more heavy isotopes.

[0037] In certain exemplary embodiments, a calibration curve is used to determine the amount of drug present.

[0038] In certain exemplary embodiments, the xHA-LP is contacted with the hyaluronidase 2 in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 5 KPSI, about 10 KPSI, or about 15 KPSI.

[0039] In certain exemplary embodiments, the oHA-LP is contacted with the Asp-N in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 35 KPSI, about 40 KPSI, or about 45 KPSI.

[0040] In another aspect, a method for determining the amount of a drug present in a cross-linked hyaluronic acid-linker-peptide (xHA-LP) prodrug formulation is provided. The method comprises the steps of: contacting the xHA-LP prodrug with HA cleavage enzyme EC4.2.2.1 to produce an oligomeric hyaluronic acid-linker-peptide drug (oHA-LP); contacting the oHA-LP with Asp-N to produce a peptide digestion product of the drug; and detecting the peptide digestion product to determine the amount of the drug present in the xHA-LP prodrug formulation.

[0041] In certain exemplary embodiments, the peptide digestion product is between about 2 amino acids and about 100 amino acids in length, between about 3 amino acids and about 75 amino acids in length, between about 4 amino acids and about 50 amino acids in length, between about 6 amino acids and about 30 amino acids in length, between about 15 amino acids and about 20 amino acids in length, or about 19 amino acids in length. In certain exemplary embodiments, the peptide digestion product is about 1, about 2, or about 3 amino acids in length.

[0042] In certain exemplary embodiments, the step of detecting the peptide digestion products is performed by a method selected from one or a combination of LC-MS, LC-MS-MS, LC-HRMS, UV absorption and fluorescence detection.

[0043] In certain exemplary embodiments, the method further comprises using an internal standard. In certain exemplary embodiments, the internal standard comprises one or more heavy isotopes.

[0044] In certain exemplary embodiments, a calibration curve is used to determine the amount of drug present.

[0045] In certain exemplary embodiments, the xHA-LP is contacted with the HA lyase EC4.2.2.1 in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 5 KPSI, about 10 KPSI, or about 15 KPSI.

[0046] In certain exemplary embodiments, the oHA-LP is contacted with the Asp-N in a pressure cycler. In certain exemplary embodiments, the pressure in the pressure cycler is greater than atmospheric pressure. In certain exemplary embodiments, the pressure is about 35 KPSI, about 40 KPSI, or about 45 KPSI. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] The foregoing and other features and advantages of the present invention will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings.

[0048] Figure 1 Depicted are a polymer carrier and a self-cleaving linker that slowly releases an active peptide drug (ie, a once-daily GLP-1 / GCC receptor agonist, SAR425899) from an inactive prodrug form in vivo.

[0049] Figure 2Depicted are the complexity and size of a weekly GLP-1 / GCG agonist (i.e., SAR425899) bound to a high molecular weight cross-linked hyaluronic acid hydrogel via a cleavable linker according to certain exemplary embodiments. D-serine is the amino acid at position 2 of SAR425899 (HdSQGTFTSDLSKQK(γE-palmitate)ESKAAQDFIEWLKAGGPSSGAPPPS-NH2).

[0050] Figure 3 Schematic depiction of digestion of SAR425899 with the intracellular protease Asp-N to produce digestion products (including the C-terminal peptide for quantification). D-serine is the amino acid at position 2 of SAR425899 (HdSQGTFTSDLSKQK(γE-palmitate)ESKAAQDFIEWLKAGGPSSGAPPPS-NH2). A calibration curve was generated using a synthetic unlabeled C-terminal peptide corresponding to the proteolytic digestion product, and a heavy isotope labeled C-terminal peptide was used as an internal standard. 20 μg to 40 μg of peptide was digested with 1.20 to 0.4 μg of Asp-N (Sigma-Aldrich) in 100 mM ammonium bicarbonate (ratio 1:100) at 37°C overnight, or digested for 1 hour at 37°C using a Pressure Bio Cycler alternating between atmospheric pressure and 40KPSI with a 1 minute cycle time.

[0051] Figure 4 The xHA-LP is shown to be digested with hyaluronidase (HAase), followed by digestion with AspN and subsequent quenching. Hydrolysis was performed at 37°C for 24 hours to release any bound intact peptides. An internal standard (IS) was added prior to LC / MS analysis. AspN completely digested SAR425899 in the presence of HA digestion products in buffer. The ratio of released intact peptide to C-terminal peptide was 0.0006.

[0052] Figure 5 It is shown that digestion of the SAR425899 prodrug with Asp-N produces a C-terminal peptide digestion product detectable by liquid chromatography / mass spectrometry (LC / MS). The SAR425899 prodrug is xHA-linker-SAR425899; SAR425899 is HdSQGTFTSDLSKQK(E-palmitate)ESKAAQDFIEWLKAGGPSSGAPPPS-NH2. The C-terminal peptide digestion product of HA-linker-SAR425899 digested with Asp-N can be detected by LC / MS, showing a moderate yield.

[0053] Figure 6 Schematic depiction of the quantification of SAR425899 prodrug cleavage. The labeled peptide internal standard (IS) refers to 13 C 15 N-Lys labeled C-terminal peptide. 200 μL of 1 mg / mL HA-linker peptide was digested with 30 μL of 100 U / mL hyaluronan lyase EC4.2.2.1 (Sigma-Aldrich) in 100 mM ammonium bicarbonate at 37° C. for 24 hours. This was followed by Asp-N digestion.

[0054] Figure 7A-7F It was shown that the HA digestion product did not produce major matrix effects. Fig. 7A Shown is HA digested with HAase 1 with the addition of a C-terminal Asp-N digestion product. Figure 7B Shown is HA digested with HAase 2 with the addition of a C-terminal Asp-N digestion product. Figure 7C is a control showing intact SAR425899 digested with Asp-N in buffer. Fig.7D Shown is HA digested with HAase 1 with the addition of the intact SAR425899 peptide. This was followed by Asp-N digestion. Fig. 7E Shown is HA digested with HAase 2 with the addition of the intact SAR425899 peptide. This was followed by Asp-N digestion. Figure 7F is a control showing intact SAR425899 digested with Asp-N in buffer. The same C-terminal peptide intensity levels were observed for both HAase digests spiked with the C-terminal peptide and the control, and for both HAase digests spiked with Asp-N digested SAR425899 and the control.

[0055] Figure 8A-B HAase 2 was shown to improve subsequent Asp-N digestion compared to HAase 1. Fig. 8A HA-linker-SAR425899 digested with HAase 1 followed by Asp-N digestion is shown. Figure 8B HA-linker-SAR425899 digested with HAase 2 followed by Asp-N is shown. The C-terminal Asp-N digestion product is shown by the peak at 956.99 m / z.

[0056] Figure 9A-9B Quantification of digestion products is shown. Fig.9A It is shown that acceptable linearity from 10 ng / mL to 10 μg / mL is observed for the standard C-terminal peptide curve. Fig. 9B Very good fragmentation of the C-terminal peptide derived from the Asp-N digest is shown, making it suitable for multiple reaction monitoring (MRM) methods.

[0057] Fig.10 Schematically depicted is the assessment of the completeness of the HAase / Asp-N digestion. A C-terminal peptide was detected, which indicates the yield of the process. An intact peptide was detected, indicating that subsequent hydrolysis released the peptide. Only 0.05% of the intact protein was detected, indicating a nearly 100% complete expected digestion process.

[0058] Figure 11A-11B Shown are cross-linked hyaluronic acid (xHA) digested with HAase in matrix and xHA digested with HAase in buffer. Fig.11A The raw data are depicted. Fig. 11B A graphical representation of the curve in matrix and the curve in buffer is depicted. Excellent linearity was observed. The curve slopes deviated from each other by 3.1%. Therefore, matrix effects were not significant, and the buffer curve could be used for quantitative analysis.

[0059] Figure 12A-12B The internal standard intensity is plotted to show no matrix effects. Consistent results were obtained in the buffer and matrix curves.

[0060] Figure 13A-13B Triplicate quantification of HA-linker peptides is shown. Good reproducibility was observed (CV of 7.4%). After applying the dilution factor, the total peptide percentage was found to be 18%.

[0061] Fig.14 Peptide (P) loading of three batches of xHA-LP is depicted, where P is SAR425899. Excellent linearity was observed with no matrix effects. Good reproducibility across replicates was observed. These results are consistent with those obtained by orthogonal NMR.

[0062] Fig.15 Depicted are the results obtained using mild hydrolysis conditions which resulted in a significant increase in the rate of enzymatic digestion.The linker-peptide intended for use as a control for peptide hydrolytic release showed high levels of synthetic impurities. DETAILED DESCRIPTION

[0063] The present invention is based on the novel quantitative method for developing the amount of the drug loaded on the polymer. In certain embodiments, the method includes cutting the hyaluronic acid (HA) present in the sample of cross-linked hyaluronic acid-linker-peptide drug (xHA-LP), to form a heterogeneous mixture of oligomeric hyaluronic acid-linker-peptide drug (oHA-LP). Then oHA-LP can be subjected to proteolytic digestion to produce homogeneous peptide digestion products, and the homogeneous peptide digestion products can be detected and quantified using methods well known in the art (such as, for example, liquid chromatography, mass spectrometry, UV absorption, fluorescence-based assays, etc.). In specific exemplary embodiments, there is provided a composition comprising xHA-LP (for example, SAR425899 prodrug), wherein "P" is peptide drug SAR425899, "L" is a self-cutting cross-linking agent, and "xHA" is a cross-linked hyaluronic acid ( Figure 2 ).

[0064] As used herein, the term "prodrug" is intended to refer to a compound that undergoes biotransformation before exhibiting its pharmacological action. Thus, a prodrug can be considered as a biologically active portion containing a dedicated non-toxic protecting group that is used in a transient manner to alter or eliminate the undesirable properties of the parent molecule. Typical prodrugs can be carrier-linked prodrugs, which contain a temporary connection of a given active substance to a transient carrier group that produces improved physicochemical or pharmacokinetic properties and can usually be easily removed in vivo by hydrolytic cleavage; cascade prodrugs, whose cleavage of the carrier group becomes effective only after exposing the activating group.

[0065] In order to enhance the physicochemical or pharmacokinetic properties of a drug (such as SAR425899) in vivo, such a drug can be conjugated to a carrier (e.g., xHA). If the drug is transiently bound to the carrier and / or linker, such a system is usually designated as a carrier-linked prodrug. According to the definition provided by IUPAC, a carrier-linked prodrug refers to a prodrug containing a temporary connection of a given active substance to a transient carrier group, which produces improved physicochemical or pharmacokinetic properties and can usually be easily removed in vivo by hydrolytic cleavage.

[0066] The linker used in the carrier-linked prodrug described herein can be any known cleavable linker or non-cleavable linker, for example, an enzyme-labile linker (e.g., an acid-cleavable linker, a reducible linker (e.g., a disulfide linker), a β-glucuronide linker, etc.), a photocleavable linker, a thioether linker, a maleimidocaproyl linker, a peptide linker (e.g., a dipeptide linker), a cross-linking agent, etc. Suitable linkers can be purchased commercially from a variety of suppliers, such as, for example, Sigma-Aldrich, Millipore Sigma, Creative Biolabs, etc.

[0067] In certain exemplary embodiments, the linkers used in the carrier-linked prodrugs described herein are transient (e.g., self-cleavable), meaning that they are non-enzymatically hydrolytically degradable (cleavable) under physiological conditions with a half-life ranging from, for example, one hour to three months.

[0068] As used herein, "physiological conditions" refers to the temperature, pH, etc., of the specific environment in the body where the drug is expected to be released. For example, release in plasma will occur at a pH between 7.35 and 7.45, at a temperature of about 37°C (e.g., between about 36°C and about 38°C), while release in lysosomes will occur at a pH between about 6.5 and about 4.5, at a temperature of about 37°C.

[0069] In certain exemplary embodiments, a drug (e.g., a peptide drug) is transiently linked to a hydrogel carrier via a self-cleaving linker (e.g., an xHA hydrogel carrier). The terms "hydrogel prodrug" and "hydrogel-linked prodrug" refer to a prodrug of a bioactive agent that is transiently linked to a hydrogel, and both are used synonymously.

[0070] The terms "drug", "peptide drug", "biologically active molecule", "biologically active moiety", "biologically active agent", "active agent", and the like refer to any substance that can affect any physical or biochemical property of a biological organism, including but not limited to viruses, bacteria, fungi, plants, animals, and humans. In particular, as used herein, biologically active molecules include any substance intended for use in diagnosing, curing, alleviating, treating, or preventing disease in humans or animals, or otherwise enhancing the physical or mental health of humans or animals. In certain exemplary embodiments, the terms "drug", "biologically active molecule", "biologically active moiety", "biologically active agent", "active agent", and the like refer to a peptide drug, such as, for example, SAR425899.

[0071] The "free form" of the drug refers to the unmodified pharmacologically active form of the drug (eg, SAR425899) as released from the hydrogel conjugate prodrug (eg, SAR425899 prodrug).

[0072] As used herein, the phrase "anti-cancer therapeutic" or "anti-cancer agent" refers to a molecule that is detrimental to the growth and / or proliferation of neoplastic cells or tumor cells or cancer cells and can act to reduce, inhibit or destroy malignancy.

[0073] As used herein, the term "cytostatic" refers to a molecule that inhibits cell growth and proliferation.

[0074] As used herein, the phrase "cytotoxic nucleoside" refers to a nucleobase or nucleoside analog that exerts a cytotoxic effect by mimicking endogenous nucleosides.

[0075] As used herein, the phrase "tubulin binding agent" refers to a molecule that directly associates with the tubulin system.

[0076] As used herein, the term "hormone" refers to any member of a class of signaling molecules produced by glands in multicellular organisms and transported to distal target organs via the circulatory system to regulate physiological function and / or behavior. A "hormone antagonist" is a specific type of receptor antagonist that acts on hormone receptors.

[0077] As used herein, the phrase "anti-angiogenic agent" refers to a molecule that inhibits the physiological process of angiogenesis, by which new blood vessels are formed from pre-existing blood vessels.

[0078] As used herein, the phrase "enzyme inhibitor" refers to a molecule that inhibits the function of a specific enzyme.

[0079] As used herein, the phrase "gene regulator" refers to a molecule that can affect gene transcription either positively or negatively.

[0080] As used herein, the phrase "cytotoxic therapeutic agent" refers to a substance that inhibits or prevents cell function and / or causes cell destruction. The term "cytotoxic agent" is intended to include chemotherapeutic agents, enzymes, antibiotics and toxins (such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof), and various anti-tumor agents or anti-cancer agents disclosed below. In some embodiments, the cytotoxic agent is a taxane, vincristine (vincas), maytansinoid alkaloids or maytansinoid alkaloid analogs (such as DM1 or DM4), small drugs, leptomycin derivatives, auristatin or dolastatin analogs, prodrugs, topoisomerase II inhibitors, DNA alkylating agents, anti-tubulin agents, CC-1065 or CC-1065 analogs.

[0081] As used herein, the phrase "pharmaceutically acceptable carrier" refers to any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, etc. that are physiologically compatible. Examples of suitable carriers, diluents and / or excipients include one or more of the following: water, amino acids, saline, phosphate buffered saline, phosphate buffer, acetate, citrate, succinate; amino acids and derivatives, such as histidine, arginine, glycine, proline, glycylglycine; inorganic salts NaCl, calcium chloride; sugars or polyols, such as glucose, glycerol, ethanol, sucrose, trehalose, mannitol; surfactants, such as polysorbate 80, polysorbate 20, poloxamer 188; etc. and combinations thereof. In many cases, it is appropriate to include an isotonic agent (such as a sugar, a polyol or sodium chloride) in the composition, and the formulation may also contain an antioxidant (such as tryptamine) and a stabilizer (such as Tween 20).

[0082] As used herein, the terms "hyaluronic acid," "HA," and "hyaluronic acid" are used interchangeably and refer to a non-sulfated linear polysaccharide composed of repeating disaccharide units of d-glucuronic acid and N-acetyl-d-glucosamine linked by β-1-3 and β-1-4 glycosidic bonds (e.g., →4)-β-d-GlcpA-(1→3)-β-d-GlcpNAc-(1→)). HA has different molecular weights. High molecular weight HA (HMWHA) is greater than about 1×10 6 Da, and low molecular weight HA (LMWHA) is about 0.8 to about 8×10 5 Da. Oligomeric HA is typically less than about 6×10 3 Da.

[0083] HA is commercially available from suppliers such as Sigma-Aldrich (St. Louis, MO), Novozymes (Blair, NE), and Stanford Chemicals (Lake Forest, CA). FDA-approved HAs include, but are not limited to, Hyalovit (Boehringer Ingelheim Vetmedica, approved for veterinary use), Hylira (Hawthorn), Hylase (ECR), Hylartin V (Zoetis, approved for veterinary use), Hyvisc (Anika Therapeutics, approved for veterinary use), Legend (Bayer Animal Health, approved for veterinary use), NexHA (Vetoquinol, approved for veterinary use), Orthovisc (DePuy Mitek), ProVisc (Alcon), Shellgell (Cytosol Opthalmics), Solesta (Salix), Supartz (Bioventus), Synacid (Intervet, approved for veterinary use), Healon5 (Abbott Medical Optics), Healon GV (Abbott), HealonEndocoat (Abbott Medical Optics), Healon (Abbott), Euflexxa (Ferring Pharmaceuticals), Equron (Zoetis, approved for veterinary use), Coease (Abbott Medical Optics), Bionect (Cipher), Amvisc (Chiron), Synvisc (Genzyme), Gel-One (Zimmer Biomet), and Hyaglan (Fidia Pharma).

[0084] To improve the mechanical properties of HA and prolong its duration in vivo, hydrogels can be formed by covalently cross-linking HA polymer chains into a three-dimensional network (see, e.g., Berg and BioDrugs 19:23; Edsman et al. (2011) Cartilage 2:384). The mechanical and physical properties of cross-linked HA (xHA) hydrogels depend on the degree of modification and cross-linking (La Gatta, Schiraldi, Papa and De Rosa (2011) Polymer Degradation and Stability 96:603;).

[0085] As used herein, the term "crosslinking agent" and "crosslinker" are intended to encompass chemical agents that can react with hyaluronic acid through at least one of covalent and / or non-covalent bonds. Non-limiting examples of non-covalent bonds include ionic bonds, hydrophobic interactions, hydrogen bonds, and van der Waals forces (dispersive attraction, dipole-dipole, and dipole-induced interactions).

[0086] As used herein, the term "crosslinking" is intended to refer to two or more hyaluronic polymer chains that have been covalently and / or non-covalently bonded via a crosslinking agent. This crosslinking is different from intermolecular or intramolecular dehydration, which results in the formation of lactones, anhydrides or esters in a single polymer chain or between two or more chains. But it can be expected that intramolecular crosslinking can also occur in the compositions described herein. The crosslinking agent contains at least two functional groups that produce covalent and / or non-covalent bonds between two or more molecules (i.e., hyaluronic acid chains). In one aspect of the present disclosure, the crosslinking agent comprises a functional group complementary to the functional group of hyaluronic acid so that crosslinking can be performed.

[0087] Physical cross-linking of HA can be achieved using various pH, temperature, ionic strength conditions and physicochemical interactions (e.g., hydrophobic interactions, hydrogen bonding, charge interactions, or stereocomplexation). In particular, temperature-responsive hydrogels have been extensively examined for various applications. Common thermogelling polymers that are often used to modify HA to prepare thermosensitive HA hydrogels include: poly (N-isopropylacrylamide) (PNIPAM), pluronic acid, methylcellulose, and polyethylene glycol (PEG).

[0088] Methods for cross-linking HA to form a hydrogel include, but are not limited to, methods for modifying -COOH groups, methods for modifying -OH groups, methods for modifying -NHCOCH3 groups, and chemical cross-linking methods using Schiff base cross-linking, dialdehyde hyaluronic acid (CHO-HA), thiol modification, Diels-Alder reaction, and enzyme-mediated connection.

[0089] Methods for cross-linking HA hydrogels are described in the following references: Kenne et al. (2013) Carb. Polymers 91:410; and Khunmanee, supra; Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer 2008; 49(8): 1993-2007; Gupta D, Tator CH, Shoichet MS. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006; 27(11): 2370–2379; Fang, JY, Chen, JP, Leu, YL. Temperature-sensitive hydrogels composed of chitosan and hyaluronic acid as injectable carriers for drug delivery. Eur J Pharm Biopharm 2008; 68(3): 626–636; and Ha DI, Lee SB, Chong MS, et al. Preparation of thermo-responsive and injectable hydrogels based on hyaluronic acid and poly(N-isopropylacrylamide) and their drug release behaviors. Macromol. Res. 2006; 14(1): 87–93, each of which is incorporated herein by reference in its entirety for all purposes.

[0090] Cross-linked HA is commercially available from suppliers such as Sigma-Aldrich (St. Louis, MO) and Stanford Chemicals (Lake Forest, CA).

[0091] As used herein, the term "hydrogel" is intended to refer to a three-dimensional, hydrophilic or amphiphilic polymer network that can absorb large amounts of water. These networks are composed of homopolymers or copolymers and are insoluble due to the presence of covalent chemical or physical (ionic, hydrophobic interactions, entanglement) crosslinks. Crosslinking provides network structure and physical integrity. Hydrogels exhibit thermodynamic compatibility with water, which allows them to swell in aqueous media. The chains of the network are connected in the following manner so that there are holes and a large portion of these holes has a size between 1nm and 1000nm.

[0092] In certain embodiments, the methods described herein utilize one or more enzymes and / or compounds to cleave xHA, for example, to cleave xHA present in xHA-LP to form oHA-LP.

[0093] Enzymes suitable for cleaving xHA include, but are not limited to, bacterial β-endoglycosidases, bacterial β-exoglycosidases (e.g., β-glucuronidase, β-N-acetyl-hexosidase, etc.), eukaryotic β-endoglycosidases (e.g., endo-β-n-acetylglucosidase, β-endoglucuronidase, etc.), eukaryotic β-exoglycosidases (e.g., β-exoglucuronidase, exo-β-N-acetylglucosaminidase, etc.), hyaluronidase, hyaluronidase, etc.

[0094] Non-enzymatic methods for cleaving xHA include, but are not limited to, acid hydrolysis, alkaline hydrolysis, ultrasonic degradation, thermal degradation, degradation by oxidants (e.g., superoxide anion radicals, hydrogen peroxide, singlet oxygen, hydroxyl radicals, nitric oxide, peroxynitrite anions, hypochlorite anions, carbonate anions, dichloride radical anions, etc.), microwave irradiation, UV irradiation, gamma irradiation, Hg lamp irradiation, etc. (See Ripka et al. (2007) Biotechnol. Adv. 25:537, which is incorporated herein by reference in its entirety for all purposes.)

[0095] In other embodiments, the methods described herein utilize one or more hyaluronoglucosidases (e.g., hyaluronidase (HAase)) to cleave xHA, for example, to cleave xHA present in xHA-LP to form oHA-LP. In certain exemplary embodiments, a combination of two, three, four, five or more HAases is used to cleave xHA. In other embodiments, a single HAase is used to cleave xHA.

[0096] As used herein, "hyaluronidase" refers to a hyaluronoglucosidase that cleaves a (1->4)-linkage (EC 3.2.1.35) or (1->3)-linkage (EC 3.2.1.36) between N-acetylglucosamine and glucuronate to catalyze the degradation of HA.

[0097] There are three major classes of hyaluronidases: 1. Mammalian hyaluronidases (EC 3.2.1.35), which are endo-β-N-acetylglucosidases with tetrasaccharides and hexasaccharides as the major end products. They have hydrolytic and trans-glycosidase activity and can degrade hyaluronic acid and chondroitin sulfate (CS), especially C4-S and C6-S; 2. Bacterial hyaluronidases (EC4.2.99.1), which degrade hyaluronic acid and, to varying degrees, CS and DS. They are endo-β-N-acetylglucosidases that act by β-elimination reactions that produce mainly disaccharide end products; and 3. Hyaluronidases from leeches, other parasites, and crustaceans (EC 3.2.1.36), which are endo-β-glucuronidases that produce tetrasaccharide and hexasaccharide end products by hydrolysis of β1-3 linkages.

[0098] Mammalian hyaluronidase can be further divided into two categories: neutral active enzyme and acid active enzyme. There are six hyaluronidase-like genes in the human genome, namely HYAL1, HYAL2, HYAL3, HYAL4, HYALP1 and PH20 / SPAM1. HYALP1 is a pseudogene, and HYAL3 has not yet been shown to have enzyme activity for any known substrate. HYAL4 is a chondroitinase, and lacks activity for hyaluronic acid. HYAL1 (also referred to as LUCA1, MPS9 and NAT6) is a prototype acid-active enzyme, and PH20 is a prototype neutral-active enzyme. Acid active hyaluronidase (such as HYAL1 and HYAL2) lacks catalytic activity at neutral pH. For example, HYAL1 has no catalytic activity (Frost et al. (1997) Anal. Biochemistry) under in vitro conditions exceeding pH 4.5. HYAL2 is an acid-active enzyme with extremely low specific activity in vitro.

[0099] HYAL5 is a HAase originally discovered in mice and is localized in plasma and on the acrosomal membrane of acrosome-intact spermatozoa released during the acrosome reaction. HYAL6 is a HAase also found in mice.

[0100] Chemical grade HAase is commercially available from suppliers such as Sigma-Aldrich (St. Louis, Missouri), Millipore Sigma (Burlington, Mass.), and Calzyme Laboratories (San Luis Obispo, Calif.). FDA-approved HAases include, but are not limited to, Amphadase (bovine hyaluronidase; New Drug Application (NDA) No. 021665; Amphastar Pharmaceuticals), Hydase (bovine hyaluronidase; NDA No. 021716; Akorn Inc.), Hylenex (recombinant human hyaluronidase; NDA No. 021859; Halozyme); Vitrase (ovine hyaluronidase; NDA No. 021640; Bausch and Lomb), and Wydase (bovine hyaluronidase; NDA No. 006343; Baxter Healthcare).

[0101] Other suitable HAases for use herein are described in the following references: World Wide Web site: brenda-enzymes.org / enzyme.php? ecno=3.2.1.35; Karl Meyer and Maurice M. Rapport'schapter on "Hyaluronidases" Advances in Enzymology-and Related Areas of Molecular Biology Pages 199-236 Volume 13 (doi.org / 10.1002 / 9780470122587.ch6); Stern and Jedrzejas Chem.Rev.2006,106,818-839Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action; Stern and Jedrzejas, Chem.Rev.2008,108,5061–5085; Yoshida et al. (2013) "KIAA1199, A deafness gene of unknown function, is a newhyaluronan binding protein involved in hyaluronan depolymerization. Proc. Natl. Acad. Sci. USA 110, 5612–5617; Nagaoka et al. 2015 Regulation of Hyaluronan (HA) Metabolism Mediated by HYBID, doi: 10.1074 / jbc.M115.673566, originally published online on October 30, 2015; Yoshino et al. 2018 Biochemical and Biophysical Research Communications Vol. 505, No. 1, October 20, 2018; Yamaguchi et al. 2019 (Matrix Biol. (2019) 78-79, 139–146 TMEM2: A missing link in hyaluronan catabolism identified?; each of the above references is incorporated herein by reference in its entirety for all purposes.

[0102] "Hyaluronidase lyase", "hyaluronan lyase", "HA lyase", "EC 4.2.2.1" or "HA lyase 4.2.2.1" refers to a hyaluronan glucosidase (i.e., a bacterial carbon-oxygen lyase) that cleaves hyaluronic acid chains at the β-D-GalNAc-(1->4)-β-D-GlcA bond, ultimately digesting the polysaccharide to 3-(4-deoxy-β-D-glucos-4-enonoyl)-N-acetyl-D-glucosamine. Hyaluronan lyases can be isolated from bacteria and Streptomyces and are distinguished from hyaluronidases from other sources by their mode of action, as they catalyze the elimination reaction of the β1,4-glycosidic linkage between N-acetyl-β-D-glucosamine and a D-glucuronic acid residue rather than hydrolysis.

[0103] In other embodiments, the methods described herein utilize one or more proteolytic enzymes (e.g., enzymes that catalyze proteolysis by cleaving peptide bonds via hydrolysis) to cleave peptides, for example, cleaving P present in xHA-LP to form oHA-LP. Suitable proteases include, but are not limited to, serine proteases, cysteine ​​proteases, threonine proteases, aspartic proteases, glutamic proteases, metalloproteases, asparagine peptide lyases, and the like. Suitable proteases classified by the optimal pH in which they are active include, but are not limited to, acidic proteases, neutral proteases, and alkaline proteases. In certain exemplary embodiments, a combination of two, three, four, five, or more proteolytic enzymes is used to cleave the peptide. In other embodiments, a single proteolytic enzyme is used to cleave the peptide.

[0104] In certain embodiments, the methods described herein utilize one or more enzymes and / or compounds to cleave a peptide drug that exists as a free drug or a prodrug (e.g., as free SAR425899 or as a SAR425899 prodrug) to produce a peptide digestion product of the drug or prodrug.

[0105] In certain embodiments, the methods described herein utilize one or more intracellular proteases to cleave a peptide drug present as a free drug or prodrug (e.g., as free SAR425899 or as a SAR425899 prodrug) to produce a peptide digestion product of the drug or prodrug. The criteria for selecting an appropriate intracellular protease are as follows: 1) produce as few high-specific fragments as possible; 2) produce a C-terminal fragment that does not contain glutamate-palmitate attached to lysine; and 3) use a common commercially available enzyme.

[0106] Suitable intracellular proteases include, but are not limited to, Glu-C, Asp-N, Lys-C, Arg-C, trypsin, and chymotrypsin. In certain exemplary embodiments, the intracellular protease Asp-N is used in the methods described herein. Various suitable intracellular proteases can be commercially available from companies such as Sigma-Aldrich (St. Louis, Missouri), New England Biolabs (Ipswich, Massachusetts), Thermo Scientific (Lenexa, Kansas), and Promega (Fitchburg, Wisconsin).

[0107] In certain embodiments, a pressure cycler can be used to improve (e.g., shorten) xHA and / or oHA digestion time. In certain embodiments, xHA and / or oHA digestion can be performed in a pressure cycler at a cycling pressure in a range between about 5 KPSI and about 80 KPSI (e.g., at about 5 KPSI, about 10 KPSI, about 15 KPSI, about 20 KPSI, about 25 KPSI, about 30 KPSI, about 35 KPSI, about 40 KPSI, about 45 KPSI, about 50 KPSI, about 55 KPSI, about 60 KPSI, about 65 KPSI, about 70 KPSI, about 75 KPSI, or about 80 KPSI).

[0108] In certain embodiments, the pressure cycler is used with one or more hyaluronidase (e.g., HAase) to digest xHA at a pressure of less than about 50 KPSI, less than about 40 KPSI, less than about 30 KPSI, or less than about 20 KPSI. In certain embodiments, the pressure cycler is used with one or more hyaluronidase (e.g., HAase) to digest xHA at a pressure of about 5 KPSI, about 10 KPSI, or about 15 KPSI. In certain embodiments, the pressure cycler is used with one or more hyaluronidase (e.g., HAase) to digest xHA at a pressure of about 10 KPSI.

[0109] In certain embodiments, the pressure cycler is used with one or more enzymes (e.g., intracellular proteases, proteases, Glu-C, Asp-N, Lys-C, Arg-C, trypsin, chymotrypsin, etc.) to digest peptides at a pressure of less than about 80 KPSI, less than about 70 KPSI, less than about 60 KPSI, or less than about 500 KPSI. In certain embodiments, the pressure cycler is used with one or more enzymes (e.g., intracellular proteases, proteases, Glu-C, Asp-N, Lys-C, Arg-C, trypsin, chymotrypsin, etc.) to digest peptides at a pressure of about 35 KPSI, about 40 KPSI, or about 45 KPSI. In certain embodiments, the pressure cycler is used with one or more enzymes (e.g., intracellular proteases, proteases, Glu-C, Asp-N, Lys-C, Arg-C, trypsin, chymotrypsin, etc.) to digest peptides at a pressure of about 40 KPSI.

[0110] In certain embodiments, the pressure cycler reduces the peptide, xHA and / or oHA digestion time by at least about one hour, about two hours, about three hours, about four hours, about five hours, about six hours, about seven hours, about eight hours, about nine hours, about ten hours, about eleven hours, about twelve hours, about thirteen hours, about fourteen hours, about fifteen hours, about sixteen hours, about seventeen hours, about eighteen hours, about nineteen hours, about twenty hours, about twenty-one hours, about twenty-two hours, about twenty-three hours, about twenty-four hours, or more, compared to digestion under non-pressurized conditions.

[0111] As used herein, "peptide digestion product" refers to any part or portion of a peptide drug (e.g., free drug or prodrug) produced by an enzyme and smaller than the intact peptide drug. In certain exemplary embodiments, the peptide digestion product is less than 50 amino acids in length, such as between about 2 and about 100 amino acids in length, between about 3 and about 75 amino acids in length, between about 2 and about 50 amino acids in length, between about 4 and about 50 amino acids in length, between about 5 and about 40 amino acids in length, between about 6 and about 30 amino acids in length, or between about 15 and about 20 amino acids in length, or any value or sub-range within these ranges. In certain exemplary embodiments, the length of the peptide digest product is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, 4, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 61, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, about 75, About 76, about 77, about 78, about 79, about 80, about 81, about 82, about 83, about 84, about 85, about 86, about 87, about 88, about 89, about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99 or about 100 amino acids.

[0112] In certain embodiments, the peptide digestion products are about 19 amino acids in length. In other certain embodiments, the peptide digestion products are about 1, about 2, or about 3 amino acids in length. In still other certain embodiments, the peptide digestion products are between about 4 and about 50 amino acids in length. In still other certain embodiments, the peptide digestion products are between about 15 and about 20 amino acids in length.

[0113] In certain exemplary embodiments, the peptide digestion products are detected using the following peptide identification methods: such as liquid chromatography-mass spectrometry (LC-MS), liquid chromatography-tandem mass spectrometry (LC-MS-MS), liquid chromatography-high resolution mass spectrometry (LC-HRMS), nano-LC-MS-MS, high performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS), nano-HPLC-MS-MS, ultra-high performance tandem MS (UPLC-MS-MS), nano-UPLC-MS-MS, ultra-high performance tandem MS (UHPLC-MS-MS), nano-UHPLC-MS-MS, ultraviolet (UV) spectroscopy, fluorescence spectroscopy, etc.

[0114] In certain exemplary embodiments, the methods described herein utilize a separation process such as chromatography (e.g., liquid chromatography). According to embodiments, detection of the peptide digestion products is performed by: (i) high performance liquid chromatography ("HPLC"), (ii) anion exchange, (iii) anion exchange chromatography; (iv) cation exchange; (v) cation exchange chromatography; (vi) ion pair reverse phase chromatography; (vii) chromatography; (viii) unidirectional electrophoresis; (ix) multidirectional electrophoresis; (x) size exclusion; (xi) affinity; (xii) reverse phase chromatography; (xiii) capillary electrophoresis chromatography ("CEC"); (xiv) electrophoresis; (xv) ion mobility separation; (xvi) field asymmetric ion mobility separation or spectroscopy ("FAIMS"); (xvii) capillary electrophoresis; and (xviii) supercritical fluid chromatography.

[0115] The amount of the peptide digestion product can be determined by measuring a multiple reaction monitoring (MRM) transition consisting of a peptide precursor ion, one or more fragment ions and a retention time. The measurement is performed, for example, on a triple quadrupole instrument. A signature can also be obtained by combining the retention time of the intact peptide with an accurate high-resolution mass spectrometry analysis. These quantitative methods typically require labeled internal standards and external synthetic peptide calibration curves.

[0116] In certain exemplary embodiments, the internal standard used includes a labeled peptide corresponding to the peptide drug, such as a labeled C-terminal peptide corresponding to the C-terminal Asp-N digestion product of SAR425899. The internal standard typically has a known peptide sequence and is provided in a known amount. In some embodiments, the standard is spiked with one or more heavy isotopes (e.g., 13 C or 15 N) mark.

[0117] The peptide digestion profiling methods described herein can be used to measure the amount of drug present in the hydrogel prodrug formulations. The methods described herein can also be used to perform batch-to-batch reproducibility assessments.

[0118] As used herein, "sample" refers to any composition containing a peptide drug (e.g., in prodrug form). Exemplary samples include, but are not limited to, pharmaceutical compositions, dissolution or release media, etc. In certain embodiments, the sample is a hydrogel. In other embodiments, the sample is aqueous.

[0119] The sample used for the quantification methods described herein can be a therapeutic composition, such as a liquid formulation for oral, sublingual, mucosal, intradermal, subcutaneous, intravenous, intramuscular, parenteral, or administration by inhalation.

[0120] In other embodiments, the sample will include a substrate, such as a nanoparticle, a capsule, a film or tablet, or a gel (such as a hydrogel, e.g., an xHA hydrogel). The quantification methods described herein can be used to quantify the amount of a peptide drug in a substrate (such as, for example, in a nanoparticle or capsule, or in a film or hydrogel (e.g., an xHA hydrogel)). The release can be from inside the substrate (e.g., an xHA hydrogel), or from outside the substrate (e.g., a surface). In one embodiment, the release profile is determined by performing a complete release of the peptide drug, and then determining the controlled release, such as over a period of time or under different culture or solution conditions (e.g., at different temperatures, pH, etc.). The amount of the peptide drug released in the controlled release assay is typically reported as a fraction or percentage compared to the amount of the peptide drug released under complete release conditions.

[0121] As used herein, "a dissolution medium", "a plurality of dissolution media", "a release medium" and "a plurality of release media" refer to compositions used to provide in vitro drug release information. The dissolution or release medium can be used, for example, for quality control testing of a sample to determine the release and / or stability of a peptide drug in the sample. In selecting an appropriate dissolution or release medium, it is useful to determine the analytical target characteristics of the peptide drug (e.g., delayed release, constant release, extended release, etc.) and / or the solubility characteristics of the peptide drug. For a review of dissolution medium selection, see Martin and Gray (Journal of Validation Technology, Summer 2011).

[0122] As used herein, "release rate" refers to the rate at which a peptide drug flows from a hydrogel prodrug formulation into a surrounding medium in an in vitro release test. In an exemplary embodiment, a composition for release testing is first prepared by suspending the composition in an appropriate in vitro release medium. This is generally performed in the following manner: the buffer is replaced after centrifugation to precipitate the substrate (e.g., hydrogel), and the substrate is reconstituted under mild conditions. In certain embodiments, the assay is started by suspending the sample at 37° C. in an appropriate temperature-controlled device. Typically, samples are removed at various time points.

[0123] Those skilled in the art will readily appreciate that other suitable modifications and adaptations of the methods described herein may be performed using suitable equivalents without departing from the scope of the embodiments disclosed herein. Although certain embodiments have now been described in detail, the embodiments will be more clearly understood with reference to the following examples, which are included for illustrative purposes only and are not intended to be limiting.

[0124] Embodiment 1

[0125] Quantification of peptide drugs present in prodrug formulations

[0126] SAR425899 is a dual receptor agonist targeting glucagon and GLP1 receptors. Due to rapid clearance, it requires a once-daily dose. To reduce the frequency of dosing, the SAR425899 candidate peptide drug ( Figure 1 ) is conjugated to a polymer carrier (cross-linked hyaluronic acid (xHA)) via a self-cleaving linker to provide slow release of the active peptide drug from the inactive prodrug ( Figure 2 SAR425899 prodrug comprises cross-linked hyaluronic acid (xHA) conjugated to SAR425899 lipopeptide (P) via a self-cleaving linker (L).

[0127] The peptide loading of the hydrogel needs to be determined for drug delivery and quality control. Cross-linked hyaluronic acid forms hydrogels of millions of daltons in an aqueous environment. Simple UV measurements, typically used for basic quantification of peptides in solution, cannot be used for hydrogels because such analysis requires complete dissolution of the hydrogel-linker-peptide. Although the linker is self-cleaving, complete cleavage under physiological conditions is very slow by design and is therefore not suitable for analytical quantification methods that require confirmation that complete release has been achieved.

[0128] To address this analytical challenge and enable determination of peptide loading, a novel method was developed that allows measurement of peptide drug loading in biopolymer prodrugs as a weight / weight percentage. In principle, biopolymer-linker-peptide drugs can be applied to any small molecule (e.g., polypeptide, polynucleotide, etc.) drug that can be cleaved or hydrolyzed, and the method can be broadly applied to determine drug loading of prodrugs containing biopolymers.

[0129] Described method is based on dual enzymatic digestion, and then the digestion product of representative peptide is quantified.First, cross-linked hyaluronic acid-joint-peptide (xHA-LP) is digested with the enzyme of digesting cross-linked hyaluronic acid.Proteolytic enzyme is used subsequently to digest the peptide attached and produce protein hydrolysis digestion product.The protein hydrolysis digestion product of these representative peptides is quantified subsequently.

[0130] The xHA-LP was weighed and partially dissolved in a buffer as a hydrogel. The hydrogel was enzymatically degraded into a soluble plurality of oligomeric hyaluronic acid-linker-peptides (oHA-LP). The hyaluronic acid oligomers of the resulting oHA-LP were a heterogeneous mixture consisting of peptides, linkers, and hyaluronic acid oligomers of varying lengths. The heterogeneity of oligomeric hyaluronic acid was undesirable for quantification, and for this reason a second enzymatic (e.g., proteolytic) digestion step was introduced, in which the peptide drug was partially digested to produce a homogeneous 19-amino acid C-terminal peptide digestion product DFIE...PPPS-NH2( Figure 3 ). The C-terminal peptide was detected and quantified using LC / HRMS.

[0131] Digestion of the prodrug with Asp-N without prior hyaluronan glucosidase treatment produced low yields of the C-terminal peptide, presumably due to steric hindrance of Asp-N activity by cross-linked hyaluronan ( Figure 5 ). It was determined that hydrolysis of the linker was impractical as a method of peptide release for quantification.

[0132] A HA digestion method was developed. Figure 6 . ) Digestion conditions suitable for subsequent digestion with intracellular proteases (eg, Asp-N) were used. Several enzymes (eg, HAase) capable of digesting HA were tested.

[0133] Digestion of cross-linked HA did not interfere with Asp-N digestion of free SAR425899 ( Figure 7A-7F ), and was shown to significantly increase the yield of subsequent Asp-N digestion C-terminal peptide digestion products ( Figure 8A-B ). In fact, it was determined that the digestion efficiency of the SAR425899 peptide by Asp-N proteolytic enzyme was close to 100%.

[0134] Asp-N has been shown to completely digest SAR 425899 in buffer and in the presence of HA digestion products ( Figure 4 ). HA-linker-peptide was digested in triplicate by HAase, followed by digestion with Asp-N, and quenched. Subsequent hydrolysis was performed at 37°C for 24 hours to release any bound intact peptide, and an internal standard (IS) was added prior to LC / MS analysis. The ratio of released intact peptide to C-terminal peptide was 0.0006.

[0135] HA-linker-peptide was double digested in triplicate with HAase for 2x24 hours, followed by digestion with Asp-N and quenching. Subsequent hydrolysis was performed at 37°C for 24 hours to release any bound intact peptide, and IS was added prior to LC / MS analysis. No intact peptide was observed.

[0136] HA-linker-peptide was digested in triplicate with HAase for 14 days, followed by digestion with Asp-N. No increase in C-terminal peptide was observed compared to digestion for 1 day, but the C-terminal peptide isomer was observed to elute slightly earlier than the regular C-terminal peptide.

[0137] LC / MS of the reaction products was performed as follows. Samples and standards were prepared in 25% acetonitrile (ACN), 0.1% formic acid (FA) to prevent observed adsorption problems. Separations were performed at 50°C on an Accela 1250 LC system equipped with a Luna Omega C18 column 100x2.1 mm, 100A (Part No. OOD-4742-AN) (S / N H16-168886).

[0138] Mobile phase A: 0.1% formic acid in water; Mobile phase B: ACN 0.1% formic acid; Flow rate 400 μL / min. Gradient: 5% to 50% in 7 minutes, 99% B for 30 sec, equilibration at 5% B for 2.5 min. A gradient starting at 20% B was also applied and was feasible.

[0139] The eluent was introduced into the Orbitrap ELITE using a standard HESI ESI source operating in positive ion mode. An Orbitrap resolution of 60000 @ m / z 400 was applied with an m / z range of 350-1500.

[0140] It was determined that all peptides were converted into digestion products, with no intact peptides remaining.

[0141]

[0142] Table 1. xHA was digested with HAase-1, C-terminal peptide (corresponding to the Asp-N digestion product) was added, and analyzed by LC / MS (Experiment No. 1); xHA was digested with HAase-1, full-length peptide was added, digested with Asp-N, and analyzed by LC / MS (Experiment No. 2); xHA was digested with HAase-2, C-terminal peptide corresponding to the Asp-N digest was added, and analyzed by LC / MS (Experiment No. 3); xHA was digested with HAase-2, full-length peptide was added, digested with Asp-N, and analyzed by LC / MS (Experiment No. 4); Control: full-length peptide was added, digested with Asp-N, and analyzed by LC / MS (Experiment No. 5); xHA-linker-peptide was digested with HAase-1, then digested with Asp-N, and analyzed by LC / MS (Experiment No. 6); xHA-linker-peptide was digested with HAase-2, then digested with Asp-N, and analyzed by LC / MS (Experiment No. 7).

[0143] The high yield of C-terminal peptides after sequential double digestion was demonstrated in several ways. Fig.10 . ) allowed for double digestion, followed by quenching of all enzymatic activity by boiling. Subsequently, by allowing the hydrolysis to proceed at 37°C, any intact peptides that may still be attached to hyaluronic acid via a linker were released. No intact peptides were observed or very small amounts of intact peptides were observed, indicating that the double digestion resulted in almost complete digestion of all peptide drug molecules. In a separate experiment, the release by hydrolysis followed by Asp-N digestion over 2 weeks did not produce a higher amount of C-terminal peptides than the double digestion procedure. As part of the method evaluation, analysis showed that the obtained xHA-LP batch had an 18% peptide loading, which was consistent with the results obtained for several batches showing approximately 20% loading (without wishing to be bound by scientific theory, the lower amount of 20% was attributed to water absorption of the freeze-dried material). When the freeze-dried hydrogel absorbs water, the weighted resulting amount contains a lower percentage of peptides due to the increase in water. This can reduce the percentage of peptides from 20% to 18%. The remedy is to be careful not to expose the weighted material to humid air conditions.

[0144] Cross-linked HA without peptides was digested and used as a matrix. The digestion product (matrix) was spiked with a synthetic unlabeled C-terminal peptide corresponding to the C-terminal Asp-N peptide digestion product of SAR425899 and a series of dilutions were generated. The heavy isotope labeled C-terminal peptide was used as an internal standard. The curve was compared with an equivalent curve drawn in 25% ACN and 0.1% formic acid buffer.

[0145] The curves were analyzed by LC / MS analysis to determine if the slopes were within 15% of each other, which was the minimum criterion for acceptance of the buffer calibration curve.

[0146] Peptide quantification using the methods described herein is reproducible. Three aliquots of the HA-linker peptide were weighed and digested with HAase and Asp-N. The ACN of the digest was adjusted to 25% and then further diluted 100-fold, followed by an additional 2-fold dilution by adding a heavy internal standard (H-IS). A 10-point standard curve from 10 μg / mL to 20 ng / mL was drawn using a 2-fold dilution step. The curve was further diluted 2-fold by adding H-IS at 1:1 volume: volume.

[0147] The method has a strong tolerance to the matrix. Figure 7A-7F The C-terminal peptide calibration curve in ) buffer showed the same slope as the calibration curve in the extraction matrix generated by digestion of cross-linked hyaluronic acid (xHA). Fig.9A , Fig. 9B , Fig.11A , Fig. 11B , Fig. 12A , 12B, Fig.13A and Fig. 13B . ) also determined that the matrix generated by digestion of xHA interferes with Asp-N digestion efficiency.

[0148] Several commercial hyaluronidases were tested and HAase 2 was identified as superior. It was also demonstrated that the C-terminal peptide produced a nearly complete series of fragments when subjected to gas phase collision-induced fragmentation (CID) and that these fragments exhibited intensities suitable for developing a multiple reaction monitoring quantification method MRM (LC / MS MRM) as an alternative to the high-resolution mass spectrometry-based method (quantification by LC / HRMS) applied in the initial work.

[0149] The prerequisite for UV or fluorescence detection is that the analyte is soluble. xHA-LP is insoluble. On the other hand, oHA-LP is water-soluble and can therefore be used for UV or fluorescence analysis. However, the digestion required to produce oHA-LP from xHA-LP does introduce hyaluronidase (e.g., hyaluronidase or HA lyase) into the mixture. Hyaluronidase (e.g., hyaluronidase or HA lyase) is a protein that absorbs UV itself. Therefore, hyaluronidase will be removed after the first digestion step, followed by direct UV detection. This method will be more suitable for regulated analytical development / manufacturing environments.

[0150] The peptide loading of three separate batches of xHA-LP (where P is SAR425899) was determined ( Fig.14 ). Excellent linearity was obtained without matrix effects. Repeated experiments of the entire process had good reproducibility, and the results were consistent with those obtained using orthogonal NMR. The method described herein is widely applicable and is being applied to assist formulation optimization. The method described herein is applicable to the use of a wide range of cleavable and non-cleavable linkers of polymers and peptide drugs.

[0151] Summarize

[0152] An LC / MS method was developed for analysis of HA-linker-SAR425899, SAR425899, and fragments / digestion products. Complete cleavage of SAR425899 with Asp-N was demonstrated to release the C-terminal peptide fragment for quantification. HA-linker-SAR425899 was demonstrated to be cleaved first by Asp-N, but based on the modest LC / MS response, the digestion was likely incomplete.

[0153] Several HAases were tested, and HA lyase (Sigma-Aldrich) EC 4.2.2.1 demonstrated a significant increase in the yield of Asp-N digestion products. An isotope-labeled C-terminal peptide was introduced, and the linear range was demonstrated after the adhesion problem was solved. Experiments to evaluate the digestion efficiency were performed. Examination of the matrix curve showed no matrix effect, and the matrix curve aligned well with the buffer curve, with a slope difference of only 3%. Weighing, processing and analysis in triplicate showed good reproducibility with a CV of 7.5%.

[0154] The total peptide percentage in the sample batch was found to be 18% (the water content of the sample was unknown, especially after multiple freeze-thaw (room temperature) cycles).

[0155] Example II

[0156] Pressure Cycler for Quantification of Peptide Drugs Present in Prodrug Formulations

[0157] The amount of drug loaded in the SAR425899 prodrug was determined via hydration and denaturation of the prodrug using a novel pressure cycler process. Digestion reactions SAR425899 digestion was tested with AspN (reaching 100% reaction in one hour). Conditions were identified that allowed the xHA digestion time to be shortened from 24 hours to 2 hours using a pressure cycler.

[0158] HAase appeared to be sensitive to very high pressures. Therefore, a maximum pressure of 10 KPSI was applied and higher enzyme concentrations were used. Under optimized conditions, higher oHA-LP product concentrations were observed for the 2-hour digestion assisted by the pressure cycler.

[0159] 16 samples were measured simultaneously (50-150 μL / sample). The rate of pressure increase / decrease was controlled. The shape of the pressure profile was observed (sine / square wave, etc.). The sample temperature was controlled using a built-in electric heater. The maximum pressure used was 40 KPSI. A typical measurement was from atmospheric pressure to 10-40 KPSI with a 1 Hz cycle for one hour.

[0160] AspN digestion of oHA-LPs at 40 KPSI pressure cycling once per minute at 37° C. was determined to be as effective as AspN digestion of oHA-LPs at atmospheric pressure for 12 hours at 37° C. All experiments were performed using a PressureBiosciences Bar Cycler (Model 2320EXT, South Easton, MA).

[0161] It was determined that AspN digestion performed using cycling between 40 KPSI pressure and atmospheric pressure at 1 minute intervals for 1 hour at 37° C. was as efficient as digestion performed at atmospheric pressure for 12 hours at 37° C. Similarly, digestion of HAase (EC 4.2.2.1) using cycling between 10 KPSI pressure for 2 hours with a 1 minute cycle time produced the same results (based on observed oligomers) as digestion performed at 37° C. at atmospheric pressure for 24 hours.

[0162] Typically, each new enzyme is optimized with respect to temperature and pressure, pressure profile, frequency and duration of pressure application.

[0163] The sample purity and main impurities were analyzed ( Fig.15 ). Release of intact peptide under mild hydrolysis conditions was determined (4°C, 14 days; or 37°C, 24 hours). Both release methods produced sufficient material for impurity analysis by LC / MS, down to 0.01% or less. Release was demonstrated to produce no impurities.

[0164] The linker-peptide control was analyzed at t = 0 and at full release. A high level of impurities was observed for the linker-peptide at t = 0. Impurity analysis was performed by LC / MS measurement of the released peptide.

[0165] Overall conclusion

[0166] The LC / MS method evaluation was successfully completed and implemented. Digestion conditions that produced complete AspN digestion were demonstrated. The matrix was shown not to be an issue. The method was demonstrated to have good reproducibility and linearity.

[0167] The results obtained by LC / MS are consistent with those obtained by orthogonal NMR methods. The method using a second generation pressure cycler significantly reduces the total analysis time. The method can be used as a reference method or to assist in formulation optimization studies. Methods for release and analysis of impurities have been established, e.g., release conditions have been established, and impurities have been detected and identified.

[0168] Equivalent

[0169] Without departing from the spirit or essential features of the present disclosure, the present disclosure may be implemented in other specific forms. Therefore, the aforementioned embodiments should be considered illustrative in all respects, rather than limiting the present disclosure. Therefore, the scope of the present disclosure is indicated by the appended claims rather than by the aforementioned description, and all changes within the meaning and scope of the equivalents of the claims should be included herein. Sequence Listing <110> New Company <120> Method for quantifying drug concentration in prodrug compositions <130> 705173: SA9-230PC <140> PCT / US2020 / 031605 <141> 2020-05-06 <150> 62 / 844,579 <151> 2019-05-07 <160> 2 <170> PatentIn version 3.5 <210> 1 <211> 19 <212> PRT <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: synthetic peptide" <400> 1 Asp Phe Ile Glu Trp Leu Lys Ala Gly Gly Pro Ser Ser Gly Ala Pro 1 5 10 15 Pro Pro Ser <210> 2 <211> 13 <212> PRT <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: synthetic peptide" <220> <221> MOD_RES <222> (7) <223> Glu-palm <400> 2 Asp Leu Ser Lys Gln Lys Xaa Glu Ser Lys Ala Ala Gln 1 5 10

Claims

1. A method for determining the amount of drug present in a cross-linked hyaluronic acid-linker-peptide (xHA-LP) prodrug formulation, the method comprising: contacting a sample of the xHA-LP prodrug formulation with a hyaluronoglucosidase to produce an oligomeric hyaluronic acid-linker-peptide drug (oHA-LP); contacting the oHA-LP with an intracellular protease to produce a peptide digestion product of the drug; and The peptide digestion products are assayed to determine the amount of the drug present in the xHA-LP prodrug formulation.

2. The method of claim 1, wherein the peptide digestion product is between 2 and 100 amino acids in length.

3. The method of claim 1, wherein the peptide digest product is between 3 and 75 amino acids in length.

4. The method of claim 1, wherein the peptide digest product is between 4 and 50 amino acids in length.

5. The method of claim 1, wherein the peptide digest product is between 6 and 30 amino acids in length.

6. The method of claim 1, wherein the peptide digest product is between 15 and 20 amino acids in length.

7. The method of claim 1, wherein the peptide digest product is 1, 2, 3, 19 amino acids in length or any combination thereof.

8. The method of claim 1, wherein the step of detecting the peptide digestion products is performed by one or a combination of methods selected from liquid chromatography-mass spectrometry (LC-MS), liquid chromatography tandem mass spectrometry (LC-MS-MS), liquid chromatography-high resolution mass spectrometry (LC-HRMS), ultraviolet (UV) absorption and fluorescence detection.

9. The method of claim 1, wherein the hyaluronan glucosidase is a hyaluronidase (HAase) or a hyaluronan (HA) lyase EC 4.2.2.

1.

10. The method of claim 9, wherein the HAase is selected from the group consisting of HAase 1, HAase 2, HAase 3, HAase 4, HAase 5, and HAase 6. The method according to claim 9 , wherein the HAase is HAase 1 or HAase 2.

12. The method of claim 9, wherein the HAase is HAase 2.

13. The method of claim 1, wherein the intracellular protease is selected from the group consisting of Glu-C, Asp-N, Lys-C, Arg-C, trypsin and chymotrypsin.

14. The method of claim 1, wherein the intracellular protease is Asp-N.

15. The method of claim 1, further comprising using an internal standard.

16. The method of claim 15, wherein the internal standard comprises one or more heavy isotopes.

17. The method of claim 1, wherein a calibration curve is used to determine the amount of drug present.

18. The method of claim 1, wherein the xHA-LP is contacted with the hyaluronoglucosidase in a pressure cycler.

19. The method of claim 18, wherein the pressure in the pressure cycler is greater than atmospheric pressure.

20. The method of claim 19, wherein the pressure is 5 KPSI, 10 KPSI, or 15 KPSI.

21. The method of claim 1, wherein the oHA-LP is contacted with an intracellular protease in a pressure cycler.

22. The method of claim 21, wherein the pressure in the pressure cycler is greater than atmospheric pressure.

23. The method of claim 22, wherein the pressure is 35 KPSI, 40 KPSI, or 45 KPSI.

Citation Information

Patent Citations

  • Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions

    CN102065886A

  • Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    CN102943067A

  • Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

    US20130202583A1